NASDAQ: BLUE |
| Healthcare / Biotechnology / USA |
4.40 | +0.1200 | +2.80% | Vol 7.66M | 1Y Perf -86.76% |
Jun 24th, 2022 16:00 DELAYED |
BID | 4.11 | ASK | 4.18 | ||
Open | 4.25 | Previous Close | 4.28 | ||
Pre-Market | - | After-Market | 4.34 | ||
- - | -0.06 -1.36% |
Target Price | 12.89 | Analyst Rating | Hold 3.24 | |
Potential % | 192.96 | Finscreener Ranking | ★+ 43.41 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★ 50.42 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★ 45.05 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 5.08 | Earnings Rating | Buy | |
Market Cap | 314.39M | Earnings Date | 8th Aug 2022 | |
Alpha | -0.05 | Standard Deviation | 0.17 | |
Beta | 1.69 |
Today's Price Range 4.024.49 | 52W Range 2.8733.09 | 5 Year PE Ratio Range -7.30-3.50 |
Summary:
Buy
Technical Indicators: | Buy |
Moving Averages: | Buy |
Performance | |||
---|---|---|---|
1 Week | 23.60% | ||
1 Month | 46.67% | ||
3 Months | -11.65% | ||
6 Months | -61.40% | ||
1 Year | -86.76% | ||
3 Years | -96.33% | ||
5 Years | -96.07% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -33.15 | |||
ROE last 12 Months | -105.35 | |||
ROA (5Y Avg) | -41.98 | |||
ROA last 12 Months | -72.23 | |||
ROC (5Y Avg) | -32.22 | |||
ROC last 12 Months | -82.72 | |||
Return on invested Capital Q | -29.20 | |||
Return on invested Capital Y | -20.38 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | -0.90 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-0.40 | ||||
1.01 | ||||
-42.45 | ||||
5.70 | ||||
-0.50 | ||||
-7.90 | ||||
1.03 | ||||
3.68 | ||||
165.27M | ||||
Forward PE | -1.04 | |||
PEG | -0.01 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.60 | ||||
1.80 | ||||
0.24 | ||||
0.42 | ||||
- | ||||
Leverage Ratio | 1.60 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-1 218.40 | ||||
-11 444.10 | ||||
-11 119.40 | ||||
-2 442.70 | ||||
- |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-7 187 000.00 | ||||
-0.10 | ||||
-46.11 | ||||
-0.13 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q01 2022 | -1.26 | -1.66 | -31.75 |
Q04 2021 | -1.82 | -1.82 | 0.00 |
Q03 2021 | -2.72 | -2.93 | -7.72 |
Q02 2021 | -3.26 | -3.58 | -9.82 |
Q01 2021 | -3.05 | -3.07 | -0.66 |
Q04 2020 | -3.02 | -3.01 | 0.33 |
Q03 2020 | -3.07 | -2.94 | 4.23 |
Q02 2020 | -1.91 | -0.36 | 81.15 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | -1.28 | 8.57 | Positive |
9/2022 QR | -1.14 | 19.15 | Positive |
12/2022 FY | -4.97 | 7.79 | Positive |
12/2023 FY | -2.92 | 31.13 | Positive |
Next Report Date | 8th Aug 2022 |
Estimated EPS Next Report | -1.28 |
Estimates Count | 7 |
EPS Growth Next 5 Years % | 38.20 |
Volume Overview | |
---|---|
Volume | 7.66M |
Shares Outstanding | 71.45K |
Shares Float | 50.58M |
Trades Count | 31.60K |
Dollar Volume | 32.83M |
Avg. Volume | 15.40M |
Avg. Weekly Volume | 27.40M |
Avg. Monthly Volume | 13.27M |
Avg. Quarterly Volume | 5.54M |
bluebird bio Inc. (NASDAQ: BLUE) stock closed at 4.4 per share at the end of the most recent trading day (a 2.8% change compared to the prior day closing price) with a volume of 7.66M shares and market capitalization of 314.39M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1213 people. bluebird bio Inc. CEO is Nick Leschly.
The one-year performance of bluebird bio Inc. stock is -86.76%, while year-to-date (YTD) performance is -55.96%. BLUE stock has a five-year performance of -96.07%. Its 52-week range is between 2.865 and 33.09, which gives BLUE stock a 52-week price range ratio of 5.08%
bluebird bio Inc. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 1.01, a price-to-sale (PS) ratio of -42.45, a price to cashflow ratio of 5.70, a PEG ratio of 2.32, a ROA of -72.23%, a ROC of -82.72% and a ROE of -105.35%. The company’s profit margin is -%, its EBITDA margin is -11 119.40%, and its revenue ttm is $-7 187 000.00 , which makes it $-0.10 revenue per share.
Of the last four earnings reports from bluebird bio Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.28 for the next earnings report. bluebird bio Inc.’s next earnings report date is 08th Aug 2022.
The consensus rating of Wall Street analysts for bluebird bio Inc. is Hold (3.24), with a target price of $12.89, which is +192.96% compared to the current price. The earnings rating for bluebird bio Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
bluebird bio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
bluebird bio Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 22.28, ATR14 : 0.59, CCI20 : 110.92, Chaikin Money Flow : -0.29, MACD : 0.16, Money Flow Index : 79.50, ROC : 39.24, RSI : 59.25, STOCH (14,3) : 46.48, STOCH RSI : 0.92, UO : 53.18, Williams %R : -53.52), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of bluebird bio Inc. in the last 12-months were: Andrew Obenshain (Sold 8 557 shares of value $82 093 ), Douglas G. Cole (Sold 9 942 shares of value $95 105 ), Jessica Whitten (Sold 3 393 shares of value $35 056 ), Nick Leschly (Sold 7 437 shares of value $71 143 ), Thomas J. Klima (Sold 3 753 shares of value $11 535 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Hold | Hold | Hold |
bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.
CEO: Nick Leschly
Telephone: +1 339 499-9300
Address: 60 Binney Street, Cambridge 02142, MA, US
Number of employees: 1 213
Wed, 06 Apr 2022 14:55 GMT Bluebird Bio (BLUE) Gets a Hold Rating from William Blair
- TipRanks. All rights reserved.Wed, 06 Apr 2022 12:40 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Bluebird Bio (BLUE) and Merck & Company (MRK)
- TipRanks. All rights reserved.Tue, 08 Mar 2022 12:31 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Brickell Biotech (BBI), Bluebird Bio (BLUE) and Aurinia Pharmaceuticals (AUPH)
- TipRanks. All rights reserved.Tue, 08 Mar 2022 06:32 GMT Analysts Offer Insights on Healthcare Companies: ADC Therapeutics (ADCT), Bluebird Bio (BLUE) and Oncolytics Biotech (ONCY)
- TipRanks. All rights reserved.Mon, 07 Mar 2022 16:45 GMT Bluebird Bio (BLUE) Receives a Sell from Morgan Stanley
- TipRanks. All rights reserved.Thu, 06 Jan 2022 18:43 GMT bluebird bio May Need to Raise Cash Soon
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.